Amyotrophic Lateral Sclerosis Treatment Market, By Type, By Treatment Type, By Distribution Channel, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

Description

REPORT HIGHLIGHT

Amyotrophic Lateral Sclerosis Treatment Market size was valued at US$ 674.90 Million in 2024, expanding at a CAGR of 6.30% from 2025 to 2032.

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative condition that affects the nerve cells in the brain and spinal cord, leading to muscle weakness, paralysis, and ultimately respiratory failure. The market for ALS therapies focuses on slowing the disease's progression, relieving symptoms, and improving patients' quality of life. This disorder can lead to various physical, cognitive, and social alterations. Consequently, effective management of symptoms, enhancement of life quality, and extension of lifespan generally necessitate the collaboration of a multidisciplinary team of experts.

Amyotrophic Lateral Sclerosis Treatment Market- Market Dynamics

The rising incidence and prevalence of amyotrophic lateral sclerosis (ALS), particularly in its sporadic form, significantly influences the Amyotrophic Lateral Sclerosis Treatment Market. Sporadic ALS, which represents approximately 90-95% of all ALS cases, is on the rise due to various factors, including an aging population, environmental factors, and genetic vulnerabilities. This increase in ALS cases, especially sporadic ALS, is driving the demand for effective treatment solutions. According to estimates from the Centers for Disease Control and Prevention (CDC), over 16,000 individuals in the United States are living with ALS, with around 5,000 new diagnoses made each year. Globally, the condition may impact 2 to 5 individuals per 100,000. Additionally, heightened investments from pharmaceutical companies, research institutions, and government agencies are fostering the development of new drugs, thereby creating growth opportunities for the market. However, the high costs associated with treatment may pose challenges to market expansion.

Amyotrophic Lateral Sclerosis Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.30% over the forecast period (2025-2032)

Based on Type segmentation, Sporadic ALS (sALS) was predicted to show maximum market share in the year 2024

Based on Treatment Type segmentation, Medication was the leading Treatment Type in 2024

Based on Distribution Channel segmentation, Hospital pharmacies were the leading Distribution Channel in 2024

Based on region, North America was the leading revenue generator in 2024

Amyotrophic Lateral Sclerosis Treatment Market- Segmentation Analysis:

The Global Amyotrophic Lateral Sclerosis Treatment Market is segmented based on Type, Treatment Type, Distribution Channel, and Region.

The market for Amyotrophic Lateral Sclerosis (ALS) is categorized into two segments based on type: Sporadic ALS and Familial ALS. Sporadic ALS (sALS) is the predominant form, representing approximately 90-95% of all ALS cases. Due to the absence of a definitive genetic cause for sALS, treatment approaches are primarily centered on modifying the disease, managing symptoms, and providing supportive care. The main FDA-approved medications, Riluzole and Edaravone, are utilized for both sALS and Familial ALS (fALS), thereby positioning sALS as the principal driver of market demand. Furthermore, the majority of experimental therapies, such as Masitinib and CNM-Au8, are being developed specifically for sporadic ALS to enhance market penetration.

The market is categorized into two segments based on Treatment Type: Medication, Stem Cell Therapy, and Other Treatment Types. Medication is the leading segment within the Amyotrophic Lateral Sclerosis (ALS) treatment market, serving as the primary approach for managing disease progression and alleviating symptoms. The growing demand for FDA-approved medications such as Riluzole, Edaravone, and Tofersen, coupled with ongoing clinical trials for novel therapies, propels market expansion. Medications account for the majority of spending in ALS treatment, with hospital pharmacies playing a crucial role in the administration of intravenous drugs like Edaravone. The rising prevalence of ALS and increased investments in healthcare contribute to a higher adoption rate of these drugs globally.

The market is categorized into four segments based on Distribution channels: Hospital Pharmacies, Online Providers, and Drug Stores, as well as Retail Pharmacies. Hospital pharmacies play a pivotal role in the Amyotrophic Lateral Sclerosis (ALS) treatment landscape, primarily due to their responsibility for the administration, dispensing, and management of ALS medications, particularly advanced therapies that necessitate specialized handling. These pharmacies oversee medications aimed at symptom management, which include muscle relaxants such as Baclofen and Tizanidine, along with therapies that support respiratory function. Numerous ALS clinical trials are conducted within hospital settings, granting hospital pharmacies early access to investigational drugs. Additionally, hospital pharmacists offer medication counseling and nutritional assistance to ALS patients experiencing difficulties with swallowing.

Amyotrophic Lateral Sclerosis Treatment Market- Geographical Insights

North America leads in market expansion, driven by a growing demand for gene therapies. The United States is a leader in advancements related to gene therapy, with prominent biotechnology firms and research institutions concentrating on amyotrophic lateral sclerosis (ALS). According to estimates from Springer Nature, the number of patients in the U.S. receiving gene therapy or stem cell therapy is projected to reach around 12,000 in 2020, increasing to over 340,000 by 2030. Europe ranks as the second-largest market, emphasizing clinical trials and initiatives to raise awareness about ALS. Meanwhile, the Asia Pacific region is experiencing the fastest growth, attributed to a rise in ALS cases and enhancements in healthcare infrastructure.

Amyotrophic Lateral Sclerosis Treatment Market- Competitive Landscape:

The competitive environment within the Amyotrophic Lateral Sclerosis (ALS) treatment sector is characterized by intense competition among pharmaceutical companies striving to develop effective therapies for this complex neurodegenerative disorder. This sector includes both established medications and novel treatments that are presently in clinical trials. Firms are allocating resources towards innovative approaches, including gene therapies and neuroprotective agents, to address the unmet clinical needs in ALS management. The dynamics of the ALS treatment market are in a state of continuous evolution, propelled by ongoing research and development efforts aimed at providing more effective and accessible treatment alternatives for patients.

Recent Developments:

On January 31, 2025, AB Science is set to initiate a new Phase 3 clinical trial aimed at evaluating its investigational oral therapy, masitinib, in individuals diagnosed with amyotrophic lateral sclerosis (ALS) who are experiencing typical disease progression and have not entirely lost their physical capabilities, as stated in a company announcement.

On February 7, 2025, Eledon Pharmaceuticals announced the integration of Tegoprubart as a vital component of the immunosuppression regimen during its second transplantation of a genetically modified pig kidney into a human patient.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

AB Science
Biogen Inc.
Biohaven Pharmaceutical (Pfizer, Inc.)
BrainStorm Therapeutics, Inc.
Corestemchemon Inc.
Eledon Pharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd
Ionis Pharmaceuticals, Inc.
ITF Pharma GmbH
Mitsubishi Tanabe Pharma Corporation
Otsuka America Pharmaceutical, Inc.
Sun Pharmaceutical Industries Ltd.
Others

GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

Sporadic ALS
Familial ALS

GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

Medication
Riluzole
Edaravone
Nuedexta
Other medication types
Stem cell therapy
Other treatment types

GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

Hospital Pharmacies
Online Providers
Drug Stores and Retail Pharmacies

GLOBAL AMYOTROPHIC LATERAL SCLEROSIS TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

Product Code: ANV5059

1. Amyotrophic Lateral Sclerosis Treatment Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Amyotrophic Lateral Sclerosis Treatment Market Snippet by Type
- 2.1.2. Amyotrophic Lateral Sclerosis Treatment Market Snippet by Treatment Type
- 2.1.3. Amyotrophic Lateral Sclerosis Treatment Market Snippet by Distribution Channel
- 2.1.4. Amyotrophic Lateral Sclerosis Treatment Market Snippet by Country
- 2.1.5. Amyotrophic Lateral Sclerosis Treatment Market Snippet by Region
2.2. Competitive Insights

3. Amyotrophic Lateral Sclerosis Treatment Key Market Trends

3.1. Amyotrophic Lateral Sclerosis Treatment Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Amyotrophic Lateral Sclerosis Treatment Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Amyotrophic Lateral Sclerosis Treatment Market Opportunities
3.4. Amyotrophic Lateral Sclerosis Treatment Market Future Trends

4. Amyotrophic Lateral Sclerosis Treatment Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Amyotrophic Lateral Sclerosis Treatment Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Amyotrophic Lateral Sclerosis Treatment Market Landscape

6.1. Amyotrophic Lateral Sclerosis Treatment Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Amyotrophic Lateral Sclerosis Treatment Market - By Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
- 7.1.2. Sporadic ALS
- 7.1.3. Familial ALS

8. Amyotrophic Lateral Sclerosis Treatment Market - By Treatment Type

8.1. Overview
- 8.1.1. Segment Share Analysis, By Treatment Type, 2024 & 2032 (%)
- 8.1.2. Medication
  - 8.1.2.1. Riluzole
  - 8.1.2.2. Edaravone
  - 8.1.2.3. Nuedexta
  - 8.1.2.4. Other medication types
- 8.1.3. Stem cell therapy
- 8.1.4. Other treatment types

9. Amyotrophic Lateral Sclerosis Treatment Market - By Distribution Channel

9.1. Overview
- 9.1.1. Segment Share Analysis, By Distribution Channel, 2024 & 2032 (%)
- 9.1.2. Hospital Pharmacies
- 9.1.3. Online Providers
- 9.1.4. Drug Stores and Retail Pharmacies

10. Amyotrophic Lateral Sclerosis Treatment Market- By Geography

10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
10.2. North America
- 10.2.1. Overview
- 10.2.2. Amyotrophic Lateral Sclerosis Treatment Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.2.7. U.S.
  - 10.2.7.1. Overview
  - 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.2.7.4. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.2.8. Canada
  - 10.2.8.1. Overview
  - 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.2.8.4. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.3. Europe
- 10.3.1. Overview
- 10.3.2. Amyotrophic Lateral Sclerosis Treatment Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.7. Germany
  - 10.3.7.1. Overview
  - 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.7.4. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.8. UK
  - 10.3.8.1. Overview
  - 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.8.3. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.8.4. UK Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.8.5. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.9. France
  - 10.3.9.1. Overview
  - 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.9.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.9.4. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.9.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.10. Italy
  - 10.3.10.1. Overview
  - 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.10.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.10.4. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.10.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.11. Spain
  - 10.3.11.1. Overview
  - 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.11.3. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.11.4. Spain Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.11.5. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.12. The Netherlands
  - 10.3.12.1. Overview
  - 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.12.3. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.12.4. The Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.12.5. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.13. Sweden
  - 10.3.13.1. Overview
  - 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.13.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.13.4. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.13.5. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.14. Russia
  - 10.3.14.1. Overview
  - 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.14.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.14.4. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.14.5. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.15. Poland
  - 10.3.15.1. Overview
  - 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.15.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.15.4. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.15.5. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.3.16. Rest of Europe
  - 10.3.16.1. Overview
  - 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.16.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.16.4. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.3.16.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Amyotrophic Lateral Sclerosis Treatment Key Manufacturers in Asia Pacific
- 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.4.4. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.4.5. APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 10.4.6. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.7. China
  - 10.4.7.1. Overview
  - 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.7.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.7.4. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.7.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.8. India
  - 10.4.8.1. Overview
  - 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.8.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.8.4. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.8.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.9. Japan
  - 10.4.9.1. Overview
  - 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.9.4. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.10. South Korea
  - 10.4.10.1. Overview
  - 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.10.4. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.11. Australia
  - 10.4.11.1. Overview
  - 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.11.4. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.12. Indonesia
  - 10.4.12.1. Overview
  - 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.12.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.12.4. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.12.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.13. Thailand
  - 10.4.13.1. Overview
  - 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.13.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.13.4. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.13.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.14. Philippines
  - 10.4.14.1. Overview
  - 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.14.4. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.4.15. Rest of APAC
  - 10.4.15.1. Overview
  - 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.15.4. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.5. Latin America (LATAM)
- 10.5.1. Overview
- 10.5.2. Amyotrophic Lateral Sclerosis Treatment Key Manufacturers in Latin America
- 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.5.4. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.5.5. LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 10.5.6. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.7. Brazil
  - 10.5.7.1. Overview
  - 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.7.4. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.8. Mexico
  - 10.5.8.1. Overview
  - 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.8.4. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.9. Argentina
  - 10.5.9.1. Overview
  - 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.9.4. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.10. Colombia
  - 10.5.10.1. Overview
  - 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.10.4. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.5.11. Rest of LATAM
  - 10.5.11.1. Overview
  - 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.11.4. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa (MEA)
- 10.6.1. Overview
- 10.6.2. Amyotrophic Lateral Sclerosis Treatment Key Manufacturers in Middle East and Africa
- 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.6.4. MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.6.5. MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
- 10.6.6. MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.7. Saudi Arabia
  - 10.6.7.1. Overview
  - 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.7.4. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.8. UAE
  - 10.6.8.1. Overview
  - 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.8.3. UAE Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.8.4. UAE Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.6.8.5. UAE Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.9. Israel
  - 10.6.9.1. Overview
  - 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.9.4. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.10. Turkey
  - 10.6.10.1. Overview
  - 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.10.4. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.11. Algeria
  - 10.6.11.1. Overview
  - 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.11.4. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.12. Egypt
  - 10.6.12.1. Overview
  - 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.12.4. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
- 10.6.13. Rest of MEA
  - 10.6.13.1. Overview
  - 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.13.4. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
  - 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Amyotrophic Lateral Sclerosis Treatment Industry

11.1. Competitive Dashboard
- 11.1.1. Competitive Benchmarking
- 11.1.2. Competitive Positioning
11.2. Company Profiles
- 11.2.1. AB Science
- 11.2.2. Biogen Inc.
- 11.2.3. Biohaven Pharmaceutical (Pfizer, Inc.)
- 11.2.4. BrainStorm Therapeutics, Inc.
- 11.2.5. Corestemchemon Inc.
- 11.2.6. Eledon Pharmaceuticals, Inc.
- 11.2.7. F. Hoffmann-La Roche Ltd
- 11.2.8. Ionis Pharmaceuticals, Inc.
- 11.2.9. ITF Pharma GmbH
- 11.2.10. Mitsubishi Tanabe Pharma Corporation
- 11.2.11. Otsuka America Pharmaceutical, Inc.
- 11.2.12. Sun Pharmaceutical Industries Ltd.
- 11.2.13. Others

12. 360 Degree AnalystView

13. Appendix

13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us